JP2018024670A5 - - Google Patents

Download PDF

Info

Publication number
JP2018024670A5
JP2018024670A5 JP2017154317A JP2017154317A JP2018024670A5 JP 2018024670 A5 JP2018024670 A5 JP 2018024670A5 JP 2017154317 A JP2017154317 A JP 2017154317A JP 2017154317 A JP2017154317 A JP 2017154317A JP 2018024670 A5 JP2018024670 A5 JP 2018024670A5
Authority
JP
Japan
Prior art keywords
compound
following formula
salt
formula
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017154317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018024670A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018024670A publication Critical patent/JP2018024670A/ja
Publication of JP2018024670A5 publication Critical patent/JP2018024670A5/ja
Withdrawn legal-status Critical Current

Links

JP2017154317A 2006-11-15 2017-08-09 キナーゼ活性の阻害剤 Withdrawn JP2018024670A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2006906359 2006-11-15
AU2006906359A AU2006906359A0 (en) 2006-11-15 Inhibitors of kinase activity
US90151207P 2007-02-14 2007-02-14
US60/901,512 2007-02-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015190233A Division JP2016041697A (ja) 2006-11-15 2015-09-28 キナーゼ活性の阻害剤

Publications (2)

Publication Number Publication Date
JP2018024670A JP2018024670A (ja) 2018-02-15
JP2018024670A5 true JP2018024670A5 (enExample) 2018-04-19

Family

ID=39401255

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009536562A Active JP5461189B2 (ja) 2006-11-15 2007-11-15 キナーゼ活性の阻害剤
JP2013229858A Withdrawn JP2014065713A (ja) 2006-11-15 2013-11-05 キナーゼ活性の阻害剤
JP2015078465A Active JP6444800B2 (ja) 2006-11-15 2015-04-07 キナーゼ活性の阻害剤
JP2015190233A Withdrawn JP2016041697A (ja) 2006-11-15 2015-09-28 キナーゼ活性の阻害剤
JP2017154317A Withdrawn JP2018024670A (ja) 2006-11-15 2017-08-09 キナーゼ活性の阻害剤

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2009536562A Active JP5461189B2 (ja) 2006-11-15 2007-11-15 キナーゼ活性の阻害剤
JP2013229858A Withdrawn JP2014065713A (ja) 2006-11-15 2013-11-05 キナーゼ活性の阻害剤
JP2015078465A Active JP6444800B2 (ja) 2006-11-15 2015-04-07 キナーゼ活性の阻害剤
JP2015190233A Withdrawn JP2016041697A (ja) 2006-11-15 2015-09-28 キナーゼ活性の阻害剤

Country Status (15)

Country Link
US (2) US8461161B2 (enExample)
EP (3) EP2848610B1 (enExample)
JP (5) JP5461189B2 (enExample)
AU (1) AU2007321719B2 (enExample)
CA (1) CA2701959C (enExample)
CY (1) CY1119528T1 (enExample)
DK (1) DK2848610T3 (enExample)
ES (1) ES2645947T3 (enExample)
HK (1) HK1225722A1 (enExample)
HU (1) HUE035868T2 (enExample)
LT (1) LT2848610T (enExample)
PL (1) PL2848610T3 (enExample)
PT (1) PT2848610T (enExample)
SI (1) SI2848610T1 (enExample)
WO (1) WO2008058341A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
WO2009095399A2 (en) 2008-02-01 2009-08-06 Akinion Pharmaceuticals Ab Pyrazine derivatives and their use as protein kinase inhbitors
US8772495B2 (en) 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP5727381B2 (ja) * 2008-12-24 2015-06-03 シンジェンタ リミテッド アリールアミドの製造方法
NZ594398A (en) 2009-04-03 2014-03-28 Plexxikon Inc Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof
EP2443255B1 (en) 2009-06-19 2017-03-29 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Csf1r-derived polynucleotides for medical use
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20120157439A1 (en) * 2009-08-28 2012-06-21 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
CA2780190C (en) 2009-11-06 2020-05-05 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
AU2010335231C1 (en) * 2009-12-22 2015-04-16 Merck Sharp & Dohme B.V. Amino-heteroaryl derivatives as HCN blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CN102971322B (zh) 2010-05-20 2016-02-17 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9408952B2 (en) * 2011-11-30 2016-08-09 Abbott Cardiovascular Systems Inc. Pediatric application of bioabsorbable polymer stents in infants and children with congenital heart defects
US8748097B1 (en) * 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
WO2014110198A2 (en) * 2013-01-10 2014-07-17 Zisman Lawrence S Therapeutic indications of kinase inhibitors
EP3007689B1 (en) * 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
HUE033423T2 (en) * 2013-03-15 2017-11-28 Glaxosmithkline Ip Dev Ltd Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
CN103214413B (zh) * 2013-03-22 2015-05-13 郑州泰基鸿诺药物科技有限公司 一种含杂环的三氟甲基酮化合物及其制备方法
JP6483714B2 (ja) * 2013-10-11 2019-03-13 ローレンス エス. ジスマン, 噴霧乾燥製剤
CN105829285A (zh) 2013-10-23 2016-08-03 中外制药株式会社 喹唑啉酮和异喹啉酮衍生物
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
KR20170046180A (ko) 2014-09-10 2017-04-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 형질감염 중 재배열 (ret) 억제제로서의 신규 화합물
PT3191450T (pt) 2014-09-10 2019-05-29 Glaxosmithkline Ip Dev Ltd Derivados de piridona como inibidores da quinase rearranjada durante a transfecção (ret)
CN104628659A (zh) * 2015-01-27 2015-05-20 广西师范大学 具有抗肿瘤作用的吡嗪-芳基脲衍生物及其制备方法与应用
CN108349969B (zh) 2015-07-16 2022-05-10 阵列生物制药公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018081567A1 (en) 2016-10-27 2018-05-03 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI676482B (zh) * 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體1的抑制劑及活化劑及其用途
US12133896B2 (en) 2017-03-23 2024-11-05 Kaohsiung Medical University Methods for treating or alleviating a bone-loss related disease or condition by administering a nucleic acid encoding a discoidin domain receptor 1 (DDR1) protein
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP2019138438A (ja) 2018-02-15 2019-08-22 日本精工株式会社 スピンドル装置
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
KR102329723B1 (ko) * 2019-08-30 2021-11-23 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
KR102329720B1 (ko) * 2019-08-30 2021-11-23 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
JP7761595B2 (ja) * 2020-05-25 2025-10-28 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ddr阻害物質としてのベンジルアミン誘導体
US20240150345A1 (en) * 2021-01-22 2024-05-09 Hibercell, Inc. Gcn2 modulating compounds and uses thereof
US20240228462A1 (en) 2021-05-07 2024-07-11 Gb002, Inc. Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2- yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5488231A (en) * 1977-12-22 1979-07-13 Sumitomo Chem Co Ltd 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
ES2151652T3 (es) * 1995-02-02 2001-01-01 Smithkline Beecham Plc Derivados de indol como antagonistas del receptor 5ht.
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
WO1997008135A1 (de) 1995-08-30 1997-03-06 Bayer Aktiengesellschaft Acylaminosalicylsäureamide und ihre verwendung als schädlingsbekämpfungsmittel
JPH09268169A (ja) * 1996-04-01 1997-10-14 Otsuka Chem Co Ltd サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤
DE59811528D1 (de) * 1997-04-04 2004-07-15 Aventis Pharma Gmbh Hypolipidämische Propanolaminderivate
AUPO863197A0 (en) * 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6143780A (en) * 1999-09-17 2000-11-07 Uniroyal Chemical Company, Inc. N-arylmethylthioanilide compounds useful for the inhibition of the replication of HIV
US6451823B1 (en) * 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
WO2003029210A2 (en) * 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
AU2003229370B2 (en) 2002-05-23 2009-02-26 Ym Biosciences Australia Pty Ltd Kinase inhibitors
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
NZ537155A (en) 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
AU2003248245A1 (en) * 2002-06-26 2004-01-19 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
AU2003246927A1 (en) * 2002-07-03 2004-01-23 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
KR20050029209A (ko) * 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. 화합물, 조성물 및 이의 사용방법
AU2002953255A0 (en) * 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
MXPA05008307A (es) * 2003-02-07 2005-09-20 Ono Pharmaceutical Co Compuestos de acidos carboxilicos.
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
AU2004263148B2 (en) * 2003-08-06 2008-08-21 Vertex Pharmaceuticals, Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
WO2005040152A1 (en) * 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
BRPI0417354A (pt) * 2003-12-03 2007-03-13 Cytopia Res Pty Ltd compostos inibidores de tubulina, composições e seus usos
ZA200602666B (en) * 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
US20090196912A1 (en) * 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
JP2006111553A (ja) * 2004-10-13 2006-04-27 Dainippon Sumitomo Pharma Co Ltd スルホニルオキシインドール誘導体及びそれを含有する医薬組成物
EP1831170A4 (en) * 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE
WO2006074428A2 (en) * 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of medical disorders
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy

Similar Documents

Publication Publication Date Title
JP2018024670A5 (enExample)
JP2019194236A5 (enExample)
JP2017008120A5 (enExample)
JP2018168171A5 (enExample)
JP2021502388A5 (enExample)
JP2018521020A5 (enExample)
JP2020515557A5 (enExample)
JP2017186358A5 (enExample)
JP2016153424A5 (enExample)
JP2021020948A5 (enExample)
JP2018116258A5 (enExample)
JP2019089762A5 (enExample)
JP2021502386A5 (enExample)
JP2017222697A5 (enExample)
JP2020007340A5 (enExample)
JP2018150298A5 (enExample)
JP2015199738A5 (enExample)
JP2012111758A5 (enExample)
JP2010501534A5 (enExample)
JP2018030858A5 (enExample)
JP2007522220A5 (enExample)
JP2014221779A5 (enExample)
JP2017506627A5 (enExample)
JP2015522045A5 (enExample)
JP2013532130A5 (enExample)